These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 11247328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
    Steen VD, Engel EE, Charley MR, Medsger TA.
    J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
    [Abstract] [Full Text] [Related]

  • 6. Bioactivity of prolactin in systemic sclerosis.
    La Montagna G, Meli R, Criscuolo T, D'Angelo S, Valentini G.
    Clin Exp Rheumatol; 2004 Apr; 22(2):145-50. PubMed ID: 15083880
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
    Heickendorff L, Parvez A, Bjerring P, Halkier-Sørensen L, Zachariae H.
    Acta Derm Venereol; 1991 Apr; 71(3):185-8. PubMed ID: 1678217
    [Abstract] [Full Text] [Related]

  • 10. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
    Lammi L, Kinnula V, Lähde S, Risteli J, Pääkkö P, Lakari E, Ryhänen L.
    Eur Respir J; 1997 Dec; 10(12):2725-30. PubMed ID: 9493651
    [Abstract] [Full Text] [Related]

  • 11. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis.
    Nagy Z, Czirják L.
    Clin Exp Rheumatol; 2005 Dec; 23(2):165-72. PubMed ID: 15895885
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.
    Scheja A, Akesson A, Hørslev-Petersen K.
    Scand J Rheumatol; 1992 Dec; 21(1):5-9. PubMed ID: 1570489
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
    Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K.
    Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
    [Abstract] [Full Text] [Related]

  • 18. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
    Brkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, van den Berg W, Dalm VA, Van Daele PL, Severino A, Maria NI, Guillen S, Dik WA, Beretta L, Versnel MA, Radstake T.
    Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
    [Abstract] [Full Text] [Related]

  • 19. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis.
    Kiener H, Graninger W, Machold K, Aringer M, Graninger WB.
    Clin Exp Rheumatol; 1994 Aug; 12(5):483-7. PubMed ID: 7842528
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.